Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Shawn, Candler"'
Publikováno v:
Neurology and Therapy, Vol 13, Iss 4, Pp 1315-1319 (2024)
Externí odkaz:
https://doaj.org/article/4481c9b8febe4586bf76d1f3aa50f406
Publikováno v:
Neurology and Therapy, Vol 13, Iss 4, Pp 1307-1311 (2024)
Externí odkaz:
https://doaj.org/article/a40839665d56483e99fb2f8c1afe5f16
Publikováno v:
Neurology and Therapy, Vol 12, Iss 6, Pp 1805-1820 (2023)
Abstract Narcolepsy is associated with disrupted nighttime sleep (DNS). Sodium oxybate (SXB; Xyrem®), administered twice nightly, is indicated for the treatment of cataplexy and excessive daytime sleepiness in patients 7 years or older with narcolep
Externí odkaz:
https://doaj.org/article/afed787cda9b4829b7d82d79ca02a5a9
Publikováno v:
Future Cardiology. 18:921-923
Autor:
Aatif Husain, Phyllis Zee, Eileen Leary, Wayne Macfadden, Douglas Fuller, Shawn Candler, Charles Bae
Publikováno v:
SLEEP. 46:A262-A262
Introduction Lower-sodium oxybate (LXB; Xywav®), which contains the same active moiety as higher-sodium oxybate (SXB; Xyrem®) but with 92% less sodium, is approved by the US Food and Drug Administration (FDA) for treating cataplexy or excessive day
Autor:
Charles Bae, Phyllis Zee, Eileen Leary, Wayne Macfadden, Douglas Fuller, Shawn Candler, Aatif Husain
Publikováno v:
SLEEP. 46:A268-A268
Introduction Lower-sodium oxybate (LXB; Xywav®), which contains the same active moiety as higher-sodium oxybate (SXB; Xyrem®) but with 92% less sodium, is approved by the US Food and Drug Administration (FDA) for treating cataplexy or excessive day
Publikováno v:
Sleep. 45
Publikováno v:
Journal of Experimental Pharmacology
Background Viloxazine was historically described as a norepinephrine reuptake inhibitor (NRI). Since NRIs have previously demonstrated efficacy in attention deficit/hyperactivity disorder (ADHD), viloxazine underwent contemporary investigation in the
Publikováno v:
Journal of Women's Health. 20:1505-1515
Syncope and palpitations are common complaints that all physicians confront during daily clinical practice. Single center and multicenter cohort studies have found that syncope accounts for 1%-3% of emergency department evaluations and that palpitati